Global Constrained Peptide Drugs Market Size is valued at USD 1.5 Bn in 2024 and is predicted to reach USD 6.7 Bn by the year 2034 at an 16.3% CAGR during the forecast period for 2025-2034.
Polypeptide chains with cyclic rings make up cyclic peptides. The ring structure can be created by joining the ends of the peptide together with an amide bond or another chemically stable bond such as lactone, ether, thioether, disulfide, and so on. Many biologically active cyclic peptides are produced through the process known as N-to-C (or head-to-tail) cyclization, which involves the production of amide bonds between the amino and carboxyl termini.
In clinical settings, a number of cyclic peptides from nature are employed. A variety of factors, such as an increase in the number of older individuals, an increase in the prevalence of chronic diseases, and a rise in patient knowledge of peptide therapies breakthroughs, are projected to drive the development of the market for peptide therapeutics.
The increase in product development and technical advancements is another prominent market trend that is projected to boost expansion in the future years. At first, COVID-19 had a significant effect on market expansion. For instance, according to a Frontiers article from May 2022, the pandemic led to the development of many peptide-based vaccines and medication candidates, which had a favourable impact on the management of COVID-19 infections. As a result, the pandemic greatly influenced the market's expansion. The market, however, is anticipated to have steady development during the projected period now that the epidemic has passed.
• Aileron Therapeutics, Inc.
• Bicycle Therapeutics plc
• Spexis AG
• Protagonist Therapeutics Inc.
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Creative Peptides
• Biosynth (Pepscan)
• Pepticom Ltd.
• PeptiDream Inc.
• Bio-Synthesis Inc
• CPC Scientific Inc.
• Circle Pharma
• Zealand Pharma
• Chugai Pharmaceutical Co. Ltd.
The Constrained Peptide Drugs market is segmented on the basis of Peptide Type and Potential Product. By Peptide Type, the market is segmented into Disulfide-Rich Peptides (DRPs) and Cyclic Peptides. On the basis of Potential Products, the market is segmented into BT5528, Rusfertide (PTG-300), PN-943, PN-235, and Zilucoplan (RA101495).
The pipeline-restricted peptides with either few or no licenced medications for the condition are included in the disulfide-rich peptides (DRPs) category, which is predicted to dominate the worldwide constrained peptide pharmaceuticals market. A group of peptides known as DRPs have many intramolecular disulfide bonds, which give them exceptional structural stability and bioactive characteristics. Due to their distinctive disulfide link configuration, these peptides are also known as cysteine-rich or cystine-knot peptides.
The Zilucoplan (RA101495) segment is projected to grow rapidly in the global constrained peptide drugs market. UCB Pharmaceuticals is creating Zilucoplan to treat myasthenia gravis (MG) and other complement-mediated diseases. An autoimmune condition called myasthenia gravis damages the neuromuscular junction and results in tiredness and muscle weakening. Zilucoplan is made to block the complement system's C5 protein, which is involved in inflammation and the immunological response.
Due to the growing need for anti-cancer medications, the rising incidence of cardiovascular disorders and other diseases, as well as the high demand for peptide and anticoagulant drugs, North America is anticipated to hold a sizable share of the global market for these medications throughout the forecast period. Aspects such as the rising burden of cancer and the rising frequency of cardiovascular diseases are expected to increase demand for peptide and anticoagulant medications.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.5 Bn |
|
Revenue Forecast In 2034 |
USD 6.7 Bn |
|
Growth Rate CAGR |
CAGR of 31.56 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Peptide Type and Potential Product |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Aileron Therapeutics Inc., Bicycle Therapeutics plc, Spexis AG, Protagonist Therapeutics Inc., Santhera Pharmaceuticals, Union Chimique Belge S.A. (UCB), Creative Peptides, Biosynth (Pepscan), Pepticom Ltd., PeptiDream Inc., Bio-Synthesis Inc, CPC Scientific Inc., Circle Pharma, Zealand Pharma, and Chugai Pharmaceutical Co. Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Constrained Peptide Drug Market Snapshot
Chapter 4. Global Constrained Peptide Drug Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5. Market Segmentation 1: By Peptide Type Estimates & Trend Analysis
5.1. By Peptide Type & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Peptide Type:
5.2.1. Disulfide-Rich Peptides (DRPs)
5.2.2. Cyclic Peptides
Chapter 6. Market Segmentation 2: By Potential Product Estimates & Trend Analysis
6.1. By Peptide Type & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Potential Product:
6.2.1. BT5528
6.2.2. Rusfertide (PTG-300)
6.2.3. PN-943
6.2.4. PN-235
6.2.5. Zilucoplan (RA101495)
Chapter 7. Constrained Peptide Drug Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Peptide Type, 2023-2031
7.1.2. North America Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.1.3. North America Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Constrained Peptide Drug Market revenue (US$ Million) by By Peptide Type, 2023-2031
7.2.2. Europe Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.2.3. Europe Constrained Peptide Drug Market revenue (US$ Million) by country, 2023-2031
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Constrained Peptide Drug Market revenue (US$ Million) by By Peptide Type, 2023-2031
7.3.2. Asia Pacific Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.3.3. Asia Pacific Constrained Peptide Drug Market revenue (US$ Million) by country, 2023-2031
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Constrained Peptide Drug Market revenue (US$ Million) by By Peptide Type, 2023-2031
7.4.2. Latin America Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.4.3. Latin America Constrained Peptide Drug Market revenue (US$ Million) by country, (US$ Million) 2023-2031
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. Middle East & Africa
7.5.1. Middle East & Africa Constrained Peptide Drug Market revenue (US$ Million) by By Peptide Type, (US$ Million)
7.5.2. Middle East & Africa Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.5.3. Middle East & Africa Constrained Peptide Drug Market revenue (US$ Million) by country, (US$ Million) 2023-2031
7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Aileron Therapeutics, Inc.
8.2.2. Bicycle Therapeutics plc
8.2.3. Spexis AG
8.2.4. Protagonist Therapeutics Inc.
8.2.5. Santhera Pharmaceuticals
8.2.6. Union Chimique Belge S.A. (UCB)
8.2.7. Creative Peptides
8.2.8. Biosynth (Pepscan)
8.2.9. Pepticom Ltd.
8.2.10. PeptiDream, Inc.
8.2.11. Bio-Synthesis Inc
8.2.12. CPC Scientific Inc.
8.2.13. Circle Pharma
8.2.14. Zealand Pharma
8.2.15. Chugai Pharmaceutical Co., Ltd.
Constrained Peptide Drugs Market By Peptide Type-
Constrained Peptide Drugs Market By Potential Product-
Constrained Peptide Drugs Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
